Description
Release form
Film-coated tablets
Pharmacological action
The drug Dicyclin is a low-dose monophasic oral hormonal contraceptive. The contraceptive effect is based on the interaction of various factors, the most important of which is the inhibition of ovulation and the change in viscosity of cervical mucus, as a result of which it becomes impermeable to sperm, the penetration of sperm through the cervical canal is difficult. With proper use, the Pearl index (an indicator that reflects the number of pregnancies in 100 women who use contraceptives during the year) is less than 1. If the pill is missed or if it is used incorrectly, the Pearl index can increase.
In addition to the contraceptive effect, it also has other concomitant positive properties. Among women, taking combined oral contraceptives, the cycle becomes more regular, the pain, intensity and duration of menstrual bleeding decreases, resulting in a reduced risk of iron deficiency anemia. There is also evidence of a reduction in the risk of endometrial and ovarian cancer.
The progestogen component dienogest, which is part of the preparation, is an active progestogen, it is a derivative of nortestosterone with antiandrogen activity and has a positive effect on the lilid profile, increasing the concentration of high density lipoproteins (HDL).
Indications
– oral contraception
– treatment of mild to moderate acne and seborrhea.
Contraindications
– hypersensitivity to any of the components of the drug Dicyclin – thrombosis (venous and arterial) and history of thromboembolism (including deep vein thrombosis, thromboembolism, pulmonary artery disease, myocardial infarction) preceding thrombosis (including transient ischemic attacks, angina pectoris) now or in history – multiple or pronounced risk factors for venous or arterial thrombosis, including donkey zhnennye defeat valvular atrial fibrillation, cerebrovascular disease, or coronary artery uncontrolled hypertension, volume surgery with prolonged immobilization, smoking at the age of 35 years, obesity with a body mass index> 30 kg / m2 – diabetes mellitus with diabetic angiopathy – a detected predisposition to venous or arterial thrombosis, including resistance to activated protein C, antithrombin III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia, antibodies to phospholipids, lupus antigen – severe liver disease (before the restoration and normalization of laboratory parameters of liver function) – benign or malignant tumors of the liver, including history of severe forms of arterial hypertension with blood pressure> 160/100 mm Hg – identified or suspected hormone-dependent malignant diseases of the genitals or mammary glands, including history — vaginal bleeding of unknown origin — migraine with focal neurological symptoms at present or history — pancreatitis accompanied by severe hypertriglyceridemia at present or history — severe and / or acute renal failure — pregnancy or suspicion of it — lacquer period hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome or hypersensitivity to peanuts or soy (due to the presence in the composition of the drug Dicycle lactose and soy lecithin). With caution: Risk factors for thrombosis and thromboembolism: obesity, smoking, dyslipoproteinemia, arterial hypertension, migraine without focal neurological symptoms, heart valve defects, prolonged immobilization, serious surgery, extensive trauma, hereditary predisposition to thrombosis (thrombosis, myocardial infarction or cerebrovascular accident at a young age in any of the next of kin). Other diseases in which peripheral circulatory disorders may occur are diabetes mellitus without diabetic angiopathy, phlebitis of superficial veins, systemic lupus erythematosus (SLE), hemolytic uremic syndrome, Crohn’s disease, ulcerative colitis, sickle cell anemia. Diseases that arose for the first time or worsened during pregnancy or against the background of previous use of sex hormones, for example, jaundice and / or itching due to cholestasis, gall bladder disease, porphyria, Sydenham chorea, herpes during pregnancy, history of hearing loss (associated with otosclerosis ) Endogenous depression epilepsy hereditary angioneurotic edema hypertriglyceridemia liver disease postpartum period.
Composition
1 tab. ethinyl estradiol 0.03 mg dienogest 2 mg
Dosage and administration
Inside, daily, preferably at the same time, in the order indicated on the package, with a small amount of water. Take 1 tablet per day continuously for 21 days. Taking pills from each next pack begins after a 7-day break, during which withdrawal bleeding (menstrual bleeding) is observed. It usually begins 2–3 days after the last tablet is taken and can continue until the tablet is started on a new package. In the absence of any hormonal contraceptives in the previous month, the drug begins on the first day of the menstrual cycle (on the first day of menstrual bleeding). It is allowed to start taking on the 2nd-5th day of the menstrual cycle, but in this case it is recommended to additionally use the barrier method of contraception during the first 7 days of taking the tablets from the first package. If you switch from the previous administration of other combined oral contraceptives, it is preferable to start taking the drug the day after taking the last active tablet from the previous package, but later than the next day after the usual 7-day break in taking (for drugs containing 21 tablets) or after taking the last inactive tablets (for preparations containing 28 tablets per pack). When moving from the vaginal ring of the transdermal patch, it is preferable to start taking Dicyclin on the day the ring or patch is removed, but no later than the day when a new ring is to be inserted or a new patch is glued. When switching from contraceptives containing only progestogens (“mini-drank”, injection forms, implant), the drug is taken: from “mini-drank” – any day (without a break), from the implant – on the day of its removal, from the injection form – from the day the next injection should have been made. In all cases, it is necessary to use an additional barrier method of contraception during the first 7 days of taking the tablets. After an abortion in the first trimester of pregnancy, you can start taking it immediately. If this condition is met, there is no need for additional contraceptive protection. After childbirth or abortion in the second trimester of pregnancy, it is recommended to start taking Dicyclinum on the 21-28th day after childbirth or abortion. If you start it later, you must use the additional barrier method of contraception during the first 7 days of taking the pill. However, if a woman has already lived sexually, pregnancy should be ruled out before the start of taking the drugs or it is necessary to wait for the first menstruation. Recommendations in case of irregular administration of the drug Dicyclin: If you missed the drug if the delay in taking the pill was less than 12 hours, the contraceptive protection does not decrease. You must take the pill as soon as possible, the next pill is taken at the usual time. If the delay in taking the pill was more than 12 hours, contraceptive protection may be reduced. In the first 2 weeks of taking the drug, if the interval since the last pill was taken is more than 36 hours: you need to take the last missed pill as soon as possible (even if it means taking 2 tablets at the same time). The next tablet is taken at the usual time. Additionally, a barrier method of contraception (condom) should be used over the next 7 days. If there was sexual intercourse within 1 week before skipping a pill, you must consider the likelihood of pregnancy. The more tablets missed and the closer this pass to the 7-day break in taking the drug, the higher the risk of pregnancy. At the 3rd week of taking the drug, if the interval from the moment of taking the last pill is more than 36 hours: you need to take the last missed pill as soon as possible (even if this means taking 2 tablets at the same time). The next tablet is taken at the usual time. Additionally, a barrier method of contraception (condom) should be used over the next 7 days. In addition, taking a pill from a new package should be started as soon as the current package is over i.e. nonstop. Most likely, there will be no withdrawal bleeding until the end of taking the tablets from the second package, but spotting or uterine bleeding of the breakthrough on the days of taking the tablets may be observed. If a woman missed taking the pill and then during the break in taking the drug she does not have withdrawal bleeding, pregnancy must be excluded. In case of gastrointestinal upsets: If a woman has vomiting or diarrhea within 3 to 4 hours after taking Dicyclin, absorption may not be complete. In this case, it is necessary to focus on recommendations regarding skipping pills. If a woman does not want to change the normal regimen of taking the drug, she must take, if necessary, an additional tablet from a spare package. Change in the day of the onset of menstrual bleeding: To delay the onset of menstrual bleeding, it is necessary to continue taking tablets from the new package immediately after all tablets from the previous one have been taken, without interruption in intake. Tablets from new packaging may be taken until the packaging is complete. Against the background of taking the drug from the second package, a woman may experience spotting or uterine breakthrough bleeding. Resume taking the drug from a new pack should be after the usual 7-day break. For, in order to postpone the day of the onset of menstrual bleeding to another day of the week, it is necessary to shorten the immediate interval in taking Dicyclin tablets by as many days as you need to postpone the day of the onset of menstrual bleeding. The shorter the interval, the higher the risk of the absence of withdrawal bleeding and the appearance of further spotting and breakthrough bleeding during the administration of tablets from the second package (as well as in the case of delaying the onset of menstrual bleeding).
Terms of delivery from
pharmacies Prescription
dosage form
tablets
Indications for kontratseptsyy, Uhrevaya s p, seborrhea
Laboratory of Leon Pharma A.A, Spain i
